CNS lymphoma is a rare cancer that forms in the brain, spinal cord, or the membranes surrounding them. It develops from white blood cells called lymphocytes that become cancerous within the central nervous system. About 90 to 95% of cases involve a specific type of immune cell called a B cell, making it a form of non-Hodgkin lymphoma that happens to grow in one of the body’s most protected and difficult-to-treat locations.
Primary vs. Secondary CNS Lymphoma
There are two distinct forms of this disease, and the distinction matters because they behave differently and carry different outlooks.
Primary CNS lymphoma (PCNSL) starts inside the central nervous system itself, with no evidence of cancer elsewhere in the body. This is unusual because the brain is considered an “immune-privileged” site, meaning the immune system operates differently there. Lymphocytes don’t normally patrol the brain the way they do the rest of the body, so how they become cancerous in this location is still not fully understood. PCNSL can also arise in the eye’s vitreous and retinal compartments, which share this immune-privileged status.
Secondary CNS lymphoma starts as a lymphoma somewhere else in the body and later spreads to the brain or spinal cord. This can happen through the bloodstream, by growing along nerve bundles, or by direct extension from nearby bone marrow. Patients with aggressive systemic non-Hodgkin lymphoma have a 2% to 27% risk of the cancer eventually reaching the central nervous system. When it does, the prognosis is significantly worse, with a median survival of about 2.2 months after that spread is detected.
Who Is Most at Risk
The median age at diagnosis for brain cancers overall is 61, and PCNSL follows a similar pattern, most commonly appearing in older adults. The disease affects both men and women, though it remains rare compared to other cancers.
People with weakened immune systems face a substantially higher risk. In people living with HIV, CNS lymphoma tends to appear when the immune system is severely compromised, typically when a specific type of immune cell count drops below 100 cells per microliter. In these cases, the cancer is almost always driven by Epstein-Barr virus (the same virus that causes mono). A healthy immune system normally keeps this virus in check, but when that surveillance fails, the virus can trigger uncontrolled growth of B cells in the brain. People who take immune-suppressing medications after organ transplants face a similar elevated risk.
Common Symptoms
CNS lymphoma symptoms depend on where the tumor grows, but they tend to develop over weeks rather than suddenly. In a large study of patients with PCNSL involving the eye, the most common complaints at diagnosis were ocular symptoms (62% of patients), including blurred vision, floaters, or worsening visual sharpness. Behavioral and cognitive changes were next most common, affecting 27% of patients.
Other symptoms included weakness on one side of the body (14%), headaches (14%), difficulty with speech (11%), seizures (5%), and problems with balance and coordination (4%). Some patients presented with only eye symptoms and no obvious neurological problems, which can delay the correct diagnosis since these complaints overlap with many less serious conditions.
How It Is Diagnosed
Contrast-enhanced MRI is the primary imaging tool for detecting CNS lymphoma. In people with healthy immune systems, the tumors typically show up as brightly enhancing masses that often cross the corpus callosum, the thick band of nerve fibers connecting the two halves of the brain. This crossing pattern is one of the imaging clues that suggests lymphoma rather than other brain tumors.
One important complication: steroids, which are frequently given to reduce brain swelling before a diagnosis is confirmed, can temporarily shrink or even make the tumor invisible on MRI. This happens because steroids affect how the blood-brain barrier leaks contrast dye and can also directly kill lymphoma cells. If steroids have already been given, a follow-up scan is recommended before attempting a biopsy to make sure the tumor is still visible enough to sample accurately.
A stereotactic biopsy, where a needle is guided precisely into the tumor using imaging, confirms the diagnosis. Spinal fluid analysis can also help. Flow cytometry on spinal fluid can detect abnormal populations of B cells with high sensitivity, and several protein markers in the fluid have shown promise in supporting the diagnosis. Certain tiny RNA molecules in spinal fluid can distinguish CNS lymphoma from inflammatory brain conditions with over 95% accuracy in research settings, though these tests are still being validated for routine use.
Treatment Approach
Treating cancer inside the brain presents a unique challenge because the blood-brain barrier blocks most standard chemotherapy drugs from reaching the tumor. The cornerstone of initial treatment is high-dose methotrexate, a drug that can cross the blood-brain barrier when given at doses far higher than those used for other cancers. Doses typically range from 3 to 8 grams per square meter of body surface area, often combined with a targeted antibody therapy. In one retrospective analysis, doses in the 3 to 5 gram range produced an overall response rate of about 82%, with half of patients achieving complete remission, while causing fewer side effects than higher doses.
After this initial phase (called induction), patients who respond well often receive consolidation therapy to reduce the chance of the cancer returning. One option is autologous stem cell transplant, where a patient’s own stem cells are collected, high-dose chemotherapy is given to eliminate remaining cancer, and the stem cells are then returned to rebuild the blood and immune system. In one study, patients who received this approach had 2-year overall survival of 100% and 4-year overall survival of about 71%. Whole-brain radiation was once a standard consolidation option, but concerns about long-term cognitive damage, particularly in older patients, have shifted practice toward chemotherapy-based consolidation and stem cell transplant when feasible.
When the Cancer Returns
Relapsed or treatment-resistant CNS lymphoma is particularly difficult to manage. A newer class of oral medications that block a specific signaling protein inside B cells has shown meaningful activity in this setting. When used alone for relapsed disease, these drugs produce responses in about 60% of patients. When combined with chemotherapy or other treatments, response rates climb to roughly 78%, with nearly half of patients achieving complete remission. However, these responses tend to be temporary, with a median time before the disease progresses again of about 5 months. Common serious side effects include low lymphocyte counts, infections, low platelet counts, and liver enzyme elevations.
Prognosis and What Affects It
Five-year overall survival for PCNSL is approximately 61%, based on recent data. The 2-year overall survival rate is around 85%, and the 5-year progression-free survival rate (meaning the cancer hasn’t grown back) is about 34%. These numbers reflect the reality that many patients respond well initially but face recurrence.
The factors that most strongly predict outcome are how well the cancer responds to initial treatment and whether a patient receives stem cell transplant as consolidation. Achieving complete or partial remission after induction therapy was associated with a 95% reduction in the risk of disease progression. Receiving stem cell transplant consolidation reduced progression risk by about 58% compared to not receiving it.
A widely used scoring system identifies five factors that predict a worse prognosis: age over 60, poor physical functioning, elevated levels of a blood enzyme called LDH, high protein concentration in the spinal fluid, and tumor involvement of deep brain structures like the brainstem, cerebellum, or areas near the brain’s fluid-filled ventricles. Patients with fewer of these risk factors tend to do considerably better than those with several.